Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | RAD52 | P43351 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ACP1 | P24666 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751104 | 0.93 | SLC2A1 (0.61) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL16123691 | 0.93 | SLC2A1 (0.79) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL16123717 | 0.89 | SLC2A1 (0.85) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL23029630 | 0.88 | SLC2A1 (0.61) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL29636766 | 0.88 | SLC2A1 (0.61) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29636808 | 0.87 | SLC2A1 (0.60) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL6752890 | 0.87 | SLC2A1 (0.62) | SLC2A1POLBRAD52ACP1 | |
| SCHEMBL23029598 | 0.86 | ACP1 (0.71) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL23029601 | 0.85 | SLC2A1 (0.70) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL23029770 | 0.85 | SLC2A1 (0.64) | SLC2A1POLBRAD52KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | SLC2A1 3982/4885POLB 1024/4885RAD52 760/4885 |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | NQO2, MKI67, NQO1 | SLC2A1 3982/4885POLB 1024/4885RAD52 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.